Objective : To investigate the efficacy and safety of intraperitoneal chemotherapy with docetaxel combined with iv. leucovorin /fuorouracil/oxaliplatin in the treatment of advanced gastric cancer. Methods: All 43 patients with advanced gastric cancer were administered abdominal inwelling catheter conventionally. And then received docetaxel 40mg/m2 ip. on day 1 ,8; leucovorin 200mg/m2 iv. on day 1 -5 ; fuorouracil 375 mg/m2 iv. on day 1 -5 ; oxaliplatin 135mg/m2 iv. on day 1, three weeks as a cycle, each case received a total of 2 -4 cycles. Results: Overall response rate( CR + PR ) was 58. 1％( 25/43 ). mTTP was 7. 5( 2. 3 - 14. 2 ) months. One - year overall survival rate was 67. 4％ . The common side effects of intraperitoneal chemotherapy with docetaxel was abdominal pain, diarrhea, bone marrow suppression, stomatitis, alopecia, nausea, vomiting, and so on. Conclusion: Intraperitoneal chemotherapy with docetaxel ( 40mg/m2 d1,8 ip ) in the treatment of advanced gastric cancer is effective and tolerable.%目的:探讨多西紫杉醇(DOC)腹腔灌注化疗(intraperitoneal chemotherapy,IPC)联合亚叶酸钙(CF)/5-氟尿嘧啶(5-FU)/奥沙利铂(OXA)静脉用药治疗晚期胃癌的临床疗效和安全性.方法:2007年7月至2009年9月,给与43例TNM Ⅲb-Ⅳ期胃癌患者(Ⅲb期19例,Ⅳ24期例)DOC 40mg/m2腹腔灌注d1,8,CF 200mg/m2静脉滴注d1-5,5-FU 375mg/m2 静脉滴注d1-5,OXA 135mg/m2 静脉滴注d1方案,每21天为一周期,共2-4个周期,每2周期评价疗效.结果:总有效率(CR+PR)为58.1%(25/43),其中CR6.9%(3/43)、PR51.2%(22/43).中位疾病进展时间(mTTP)为7.5(2.3-14.2)个月.一年生存率为67.4%.常见不良反应为腹痛、腹泻、骨髓抑制、胃肠道反应、脱发、口腔黏膜炎和外周神经毒性等.结论:DOC 40mg/m2腹腔灌注d1,8,联合CF/5-FU/OXA方案静脉用药治疗晚期胃癌疗效肯定,且不良反应可以耐受.
展开▼
